• 한국통신학회논문지
• /
• 제27권12C호
• /
• pp.1288-1298
• /
• 2002

타원곡선 암호시스템을 GF(2$^{m}$ )상에서 고속으로 구현하기 위해서는 빠른 나눗셈기가 필요하다. 빠른 나눗셈 연산을 위해선 비트-패러럴 구조가 적합하나 타원곡선 암호시스템이 충분한 안전도를 가지기 위해서는 m의 크기가 최소한 163보다 커야 한다. 즉 비트-패러럴 구조는 0(m$^2$)의 면적 복잡도를 가지기 때문에 이러한 응용에는 적합하지 않다. 따라서, 본 논문에서는 CF(2$^{m}$ )상에서 표준기저 표기법을 사용하여 모듈러 나눗셈 A(x)/B(x) mod G(x)를 고속으로 수행하는 새로운 비트-시리얼 시스톨릭 나눗셈기를 제안한다. 효율적인 나눗셈기 구조를 얻기 위해, 새로운 바이너리 최대공약수(GCD) 알고리즘을 유도하고, 이로부터 자료의존 그래프를 얻은 후, 비트-시리얼 시스톨릭 나눗셈기를 설계한다. 본 논문에서 제안한 나눗셈기는 0(m)의 시간 및 면적 복잡도를 가지며, 연속된 입력 데이터에 대하여, 초기 5m-2 사이클의 지연 후, m 사이클 마다 나눗셈의 결과를 출력한다. 제안된 나눗셈기를 동일한 입출력 구조를 가지는 기존의 연구 결과들과 비교 분석한 결과 칩 면적 및 계산 지연시간 모두에 있어 상당한 개선을 보인다. 따라서 제안된 나눗셈기는 적은 하드웨어를 사용하면서 고속으로 나눗셈 연산을 수행할 수 있기 때문에 타원곡선 암호화시스템의 나눗셈 연산기로 매우 적합하다. 또한 제안한 구조는 기약 다항식(irreducible polynomial) 선택에 있어 어떤 제약도 두지 않고, 단 방향의 신호흐름을 가지면서, 매우 규칙적이기 때문에 필드 크기 m에 대해 높은 유연성 및 확장성을 제공한다.였다. an extraction system, a new optical nonlinear joint transform correlator(NJTC) is introduced to extract the hidden data from a stego image in real-time, in which optical correlation between the stego image and each of the stego keys is performed and from these correlation outputs the hidden data can be asily exacted in real-time. Especially, it is found that the SNRs of the correlation outputs in the proposed optical NJTC-based extraction system has been improved to 7㏈ on average by comparison with those of the conventional JTC system under the condition of having a nonlinear parameter less than k=0.4. This good experimental results might suggest a possibility of implementation of an opto-digital multiple information hiding and real-time extracting system. 촉각에 있는 지각신경세포가 뇌의 촉각엽으로 뻗어 들어가 위의 5가지 신경연접중 어느 형을 형성하는지를 관찰하기 위하여 좌측 촉각의

• Radiation Oncology Journal
• /
• 제13권3호
• /
• pp.215-223
• /
• 1995

Purpose : The aim of this study was to assess the effectiveness, survival rate and complication of radiation in nasopharyngeal cancer. Materials and Methods : From January 1980 to May 1989. Fifty patients who had nasopharyngeal carcinoma treated with curative radiation therapy at Kosin Medical Center were retrospectively studied. Thirty seven patients($74{\%}$) were treated with radiation therapy alone(Group I) and 13 patients ($26{\%}$) treated with combination of chemotherapy and radiation (Group II). Age distribution was 16-75 years(median : 45.8 years). In histologic type, squamous cell carcinoma was in 30 patients($60{\%}$), undifferentiated carcinoma in 17 patients($34{\%}$), and lymphoepithelioma in 3 patients($6{\%}$). According t AJCC staging system. 4 patients($8{\%}$) were in $T_1$, 13 patients($26{\%}$) in $T_2$. 20 patients($40{\%}$) in $T_3$, 13 patients($26{\%}$) in $T_4$ and 7 patients($14{\%}$) in $N_0$, 6 patients($12{\%}$) $N_1$, 23 patients($46{\%}$) in $N_2$, 14 patients($28{\%}$) in $N_3$. Total radiation dose ranges were 5250-9200cGy(median : 7355 cGy) in Group I and 5360-8400cGy(median : 6758cGy) in Group II Radiotherapy on 4-6MV linear accelerator and/or 6-12MeV electron in boost radiation was given with conventional technique to 26 patients($52{\%}$), with hyperfractionation(115-120cGy/fr., 2times/day) to 16 patients($32{\%}$), with accelerated fractionation(160cGy/fr., 2 times/day) to 8 patients($16{\%}$). In chemotherapy, 5 FU 1000mg daily for 5 consecutive days, pepleomycin 10mg on days 1 and 3, and cisplatin 100mg on day 1 were administered with 3weeks interval, total 1 to 3 cycles(average 1.8cycles) prior to radiation therapy. Follow up duration was 6-140 months(mean : 58 months). Statistics was calculated with Chi-square and Fisher's exact test. Results : Complete local control rates in Group I and II were $75.7{\%},\;69.2{\%} Overall 5 year survival rates in Group I and II were $56.8{\%},\;30.8{\%}$. Five year survival rates by histologic type in Group I and II were $52.2{\%},\;14.3{\%}$ is squamous cell carcinoma and $54.5{\%},\;50{\%}$ in undifferentiated carcinoma. Survival rates in Group I were superior to those of Group II though there were not statistically significant. In both group, survival rates seem to be increased according to increasing total dose of radiation up to 7500cGy, but not increased beyond it. There were not statistically significant differences in survival rates by age, stage, and radiation techniques in both group. Twenty four patients($48{\%}$) experienced treatment failures. Complications were found in 12 patients($24{\%}$). The most common one was osteomyelitis(4 patients, $33.3{\%}$) involving mandible (3 patients) and maxilla(1 patient). Conclusion : Chemotherapy in combination with radiotherapy was found to be not effective to nasopharyngeal cancer and the survival rate was also inferior to that of radiation alone group though it was statistically not significant due to small population in chemotherapy combined group.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제36권6호
• /
• pp.453-459
• /
• 2010

Introduction: Ameloblastic carcinoma is a rare malignant lesion, and may arise from either carcinoma ex-ameloblastoma or de novo carcinoma. Aberrant promoter hypermethylation of the tumor-associated genes leading to their inactivation is a common event in many cancer types. The p16/CDKN2/INK4A gene and p16 5 protein are involved directly in regulating the cell cycles. Cadherins are cell adhesion molecules that modulate the epithelial phenotype and regulate tumor invasion. The aim of this study was to evaluate the roles of p16 and E-cadherin methylation and loss of p16 and E-cadherin expression in the malignant transformation of an ameloblastoma. Materials and Methods: Eight cases of ameloblastoma, including 4 benign ameloblastomas without recurrence, 2 benign ameloblastomas with recurrence and 2 carcinoma ex-ameloblastomas, were examined. The promoter hypermethylation profile of the p16 and E-cadherin genes was studied using methylation-specific polymerase chain reaction (MSP) and immunohistochemical staining for p16 and E-cadherin expression. Results: 1) Aberrant CpG island methylation of the p16 gene was detected in 3 of the 4 benign ameloblastomas without recurrence and 1 of the 2 benign ameloblastomas with recurrence. 2) Aberrant CpG island methylation of the E-cadherin gene was found in 1 of the 4 benign ameloblastomas without recurrence. 3) A loss of p16 expression was noted in 1 of 4 benign ameloblastomas without recurrence and 1 of 2 carcinoma ex-ameloblastomas. 4) A loss of E-cadherin expression was noted in 2 of the 4 benign ameloblastomas without recurrence, 1 of the 2 benign ameloblastomas with recurrence and 2 of the 2 carcinoma ex-ameloblastomas. 5) A loss of p16 expression was observed in 1 of the 4 cases showing aberrant methylation of the p16 gene. 6) A loss of E-cadherin expression was observed in 3 benign ameloblastoma case showing aberrant methylation of the E-cadherin gene. Conclusion: These results suggest that loss of E-cadherin expression related to the other genetic pathway (not methylation) might be an adjuvant indicator predicting the malignant transformation of an ameloblastoma. However, the number of samples in this study was too small and the relationship between the treatment methods and clinical course were not defined. Therefore, further study will be needed.

• 한국환경과학회지
• /
• 제20권2호
• /
• pp.251-260
• /
• 2011

$TiO_2$- and $SiO_2$-supported $Co_3O_4$, Pt and $Co_3O_4$-Pt catalysts have been studied for CO and $C_3H_8$ oxidations at temperatures less than $250^{\circ}C$ which is a lower limit of light-off temperatures to oxidize them during emission test cycles of gasoline-fueled automotives with TWCs (three-way catalytic converters) consisting mainly of Pt, Pd and Rh. All the catalysts after appropriate activation such as calcination at $350^{\circ}C$ and reduction at $400^{\circ}C$ exhibited significant dependence on both their preparation techniques and supports upon CO oxidation at chosen temperatures. A Pt/$TiO_2$ catalyst prepared by using an ion-exchange method (IE) has much better activity for such CO oxidation because of smaller Pt nanoparticles, compared to a supported Pt obtained via an incipient wetness (IW). Supported $Co_3O_4$-only catalysts are very active for CO oxidation even at $100^{\circ}C$, but the use of $TiO_2$ as a support and the IW technique give the best performances. These effects on supports and preparation methods were indicated for $Co_3O_4$-Pt catalysts. Based on activity profiles of CO oxidation at $100^{\circ}C$ over a physical mixture of supported Pt and $Co_3O_4$ after activation under different conditions, and typical light-off temperatures of CO and unburned hydrocarbons in common TWCs as tested for $C_3H_8$ oxidation at $250^{\circ}C$ with a Pt-exchanged $SiO_2$ catalyst, this study may offer an useful approach to substitute $Co_3O_4$ for a part of platinum group metals, particularly Pt, thereby lowering the usage of the precious metals.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권17호
• /
• pp.7119-7123
• /
• 2014

Background: The role of second-line therapy in metastatic pancreatic cancer is not clear. In this study, we aimed to explore the second-line efficiency of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer who have received gemcitabine-based first-line therapy. Materials and Methods: We retrospectively evaluated 47 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine-based first-line regimens. Treatment consisted of oxaliplatin $130mg/m^2$ and capecitabine $1000mg/m^2$ twice daily with a 3 week interval, until unacceptable toxicity or disease progression. Results: Median number of cycles was 4 (range, 2-10). The overall disease control rate was 38.3%. The median overall survival and progression-free survival from the start of second-line therapy were 23 weeks (95%CI: 16.6-29.5 weeks) and 12 weeks (95%CI: 9.8-14.4 weeks), respectively. The most common grade 3-4 toxicities were nausea, vomiting and hematologic side effects. Conclusions: Our result suggests that the combination of capecitabine and oxaliplatin was tolerated with manageable toxicity and showed encouraging activity as second-line treatment of advanced or metastatic pancreatic cancer patients with ECOG performance status 0-2.

• 한국강구조학회 논문집
• /
• 제9권3호통권32호
• /
• pp.421-430
• /
• 1997

본 연구에서는 숏브라스트한 후 무기징크 페인트로 도장한 무기징크면, 연마면, 흑피면에 대하여 정적 및 피로시험을 수행하여 기존의 연구결과와 비교평가함으로써 마찰면의 표면상태에 따른 고장력볼트 마찰이음부의 정적 및 피로거동을 규명하고자 하였다. 본 연구의 목적을 달성하기 위하여 일련의 정적 및 피로시험을 실시하고 토크관리법의 타당성 평가, 미끄러짐계수의 도출, 도입축력의 감소률 규명, 피로강도의 평가, 마찰면의 압축력 분포 조사 등을 수행하였다. 본 실험결과와 기존 연구자들의 연구결과를 종합적으로 검토한 결과 볼트의 설계축력 도입을 위한 토크관리법은 타당하며, 시간경과 및 반복하중의 작용에 따른 축력감소율을 고려할 때 설계축력의 110%로 초기축력을 도입하도록 규정한 시방서 기준은 적합한 것으로 평가되었다. 시간경과에 따른 도입축력의 초기감소율은 경과시간의 상용로그에 비례하는 것으로 나타났으며, 도입직후 약 20시간이 경과하면 일정한 값으로 수렴되고 있음을 알 수 있었고 이들은 마찰면의 표면조도와는 상관관계가 없는 것으로 평가되었다. 미끄러짐계수는 연마면, 무기징크프라이머 도포면, 흑피면 순으로 크게 나타났으며 미끄러짐하중은 도입축력에 크게 좌우되나 도입축력이 크면 마찰면의 표면조도의 손상으로 인하여 미끄러짐계수가 작아져 도입축력과 미끄러짐하중 사이에는 선형적 비례관계가 성립되지 않음을 알 수 있었다. 마찰면의 압축력 분포를 조사한 결과 내측볼트 주변의 마찰면적이 외측볼트 주변보다 응력방향에 있어서 더 넓게 분포하고 있는 것을 알 수 있었으며, 이는 외측볼트로부터 마찰접합에서 지압접합으로 천이되고 있는 것으로 판단된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권20호
• /
• pp.8661-8666
• /
• 2014

Background: Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer. However, substantial toxicity has limited its use in daily clinical practice. Therefore, modification of DCF regimens, including introduction of capecitabine has been investigated to improve the safety profiles. In the present study, the efficacy and toxicity of a regimen with a modified dose of docetaxel and cisplatin in combination with oral capecitabine (DCX) was evaluated in untreated patients with HER2-negative advanced gastric cancer. Materials and Methods: Fifty-four patients with HER2-negative locally advanced or metastatic gastric cancer were included in this cohort. Patients received docetaxel $60mg/m^2$ plus cisplatin $60mg/m^2$ (day 1) combined with capecitabine $1650mg/m^2$ (days 1-14) every 3 weeks. Treatment response, survival, and toxicity were retrospectively analyzed. Results: The median age was 54 years (range: 24-76). The majority of patients (70%) had metastatic disease, while 11 patients (21%) had recurrent disease and underwent curative gastrectomy, and 5 patients (9%) had locally advanced disease (LAD). The median number of DCX cycles was 4. There were 28 partial responses and 11 complete responses, with an overall response rate of 72%. Curative surgery could be performed in four patients among five with LAD. At the median follow-up of 10 months, the median progression-free survival (PFS) and overall survival (OS) of the entire cohort of patients were 7.4 and 12.1 months, respectively. Dose modification was done in 12 patients due to toxicity in 8 and noncompliance in 4 patients. The most common hematological toxicity was neutropenia, which occurred at grade 3-4 intensity in 10 of 54 patients (27.7%). Febrile neutropenia was diagnosed only in two cases. Conclusions: DCX regimen offers prominent anti-tumor activity and considered to be effective first-line treatment with manageable toxicity for patients with HER2-negative advanced gastric cancer.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권20호
• /
• pp.9009-9013
• /
• 2014

Background: The aim of this study was to explore the efficacy and adverse reactions of CT-guided radioactive 125I-seed implantation treatment combined with chemotherapy for platinum-resistant recurrent ovarian carcinoma. Materials and Methods: From September 2010 to December 2012, 23 patients with platinum-resistant recurrent ovarian carcinoma were enrolled. All the patients refused, could not bear, or were not suitable for surgery. They all had no more than 3 lesions, which were detected and could also be measured by CT. All were clarified as single-lesion or multiple-lesion groups. A total of 41 lesions underwent implantation of from 8 to 106 125I seeds (median=43). Multi-plane implanting was adopted and 125I-seeds of (0.4-0.7)mCi were placed at intervals of (0.5-1.0) cm. After implantation treatment, all patients underwent 4 cycles of chemotherapy with gemcitabine $800mg/m^2$ (days 1, 8 and 15). Results: The outcome was evaluated with CT 3 weeks and every 3 months after implantation treatment. After 6 months, the volume of 32 out of 41 lesions (78.0%) was reduced at least 30%, within which 9 lesions completely disappeared(22.0%). Complete response was observed in 7 cases (30.4%), with a partial response in 4 cases (17.4%), 4 cases stable(17.4%)and 8 cases showing progression (34.8%). The total clinical remission rate was 47.8% (11/23). The clinical remission rate was 77.8% (7/9) in the single-lesion group and 28.6% (4/14) in the multiple-lesion group with a significant difference between the two(P=0.036). The common side effects observed were mild gastrointestinal reactions. Conclusions: 125I-seed implantation combined with chemotherapy applies an effective way in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma with the advantages of high local control rates, good short-term effects, little trauma and less side effects.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권7호
• /
• pp.3335-3341
• /
• 2014

Background: Severe toxicity is commonly observed in cancer patients receiving irinotecan (CPT-11) UDPglucuronosyltransferase1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38 but the relationship between UGT1A1 and severe toxicity remains unclear. Our study aimed to assess this point to guide clinical use of CPT-11. Materials and Methods: 89 cancer patients with advanced disease received CPT-11-based chemotherapy for at least two cycles. Toxicity, including GI and hematologic toxicity was recorded in detail and UGT1A1 variants were genotyped. Regression analysis was used to analyse relationships between these variables and tumor response. Results: The prevalence of grade III-IV diarrhea was 10.1%, this being more common in patients with the TA 6/7 genotype (5 of 22 patients, 22.7%) (p<0.05). The prevalence of grade III-IV neutropenia was 13.4%and also highest in patients with the TA 6/7 genotype (4 of 22 patients; 18.2%) but without significance (p>0.05). The retreatment total bilirubin levels were significantly higher in TA6/7 patients (mean, $12.75{\mu}mol/L$) with compared to TA6/6 (mean, $9.92{\mu}mol/L$) with p<0.05. Conclusions: Our study support the conclusion that patients with a $UGT1A1^*28$ allele (s) will suffer an increased risk of severe irinotecan-induced diarrhea, whether with mid-or low-dosage. However, the $UGT1A1^*28$ allele (s) did not increase severe neutropenia. Higher serum total bilirubin is an indication that patients UGT1A1 genotype is not wild-type, with significance for clinic usage of CPT-11.

• 생물환경조절학회지
• /
• 제26권3호
• /
• pp.167-174
• /
• 2017

본 연구는 우리나라의 대표적인 조림수종인 소나무를 대상으로 조림지 식재 후 활착률을 높이기 위해 상대적으로 생육이 좋은 용기묘로 생산하고자 할 때, 관수처리 수준에 따른 생장 반응 특성을 조사하고 이를 통하여 적정 관수 수준을 구명하고자 실시되었다. 104구 용기에서 생육된 소나무 용기묘는 대조구(무관수)를 포함하여 파종 후 15주부터 8주 동안 각각 1, 2, 3, 5, 7, 10, 15일 간격으로 관수되었다. 관수처리에 따른 소나무 용기묘의 간장과 근원경 생장, 건물생산량을 조사한 결과 가장 좋은 생장 반응은 관수처리 1일 간격에서 가장 높게 나타났다. 관수주기가 짧아질수록 소나무 용기묘의 생장이 좋아졌지만, 전체뿌리길이는 2일이나 1일 관수주기보다 3일에서 더 높게 나타났다. 묘목품질지수의 경우 1일 간격에서 가장 높고 관수주기가 길어질수록 낮아지는 경향을 보였다. 본 연구결과를 종합하면 1~2일 간격의 관수가 소나무 용기묘의 생육에 있어 적합한 것으로 판단된다.